SGLT-2 inhibition in IgA nephropathy: the new standard of care?
- 1 July 2021
- journal article
- editorial
- Published by Elsevier in Kidney International
- Vol. 100 (1) , 24-26
Abstract
No abstract availableKeywords
Funding Information
- RWTH Aachen
This publication has 7 references indexed in Scilit:
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathyKidney International, 2021
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathyKidney International, 2020
- Evaluating a New International Risk-Prediction Tool in IgA NephropathyJAMA Internal Medicine, 2019
- Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2019
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA NephropathyJAMA, 2017
- Intensive Supportive Care plus Immunosuppression in IgA NephropathyNew England Journal of Medicine, 2015